Drug Trial Radar · NCT02199691
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,715
Actual
Start
Jul 22, 2014
Primary completion
Oct 2, 2015
Study completion Oct 2, 2015
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine. Primary objective: * To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine when MenACYW Conjugate vaccine was given alone compared to those when MENVEO vaccine was given alone. Secondary objective: * To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with Tdap and HPV vaccines, compared to those when it was given alone. * To evaluate the antibody responses to the antigens present in Tdap vaccine, when Tdap vaccine was given concomitantly with MenACYW Conjugate vaccine and HPV vaccine, compared to those when Tdap vaccine was given with HPV vaccine only. * To evaluate the antibody responses to the antigens present in HPV vaccine after the 3-dose series, when the first dose of HPV vaccine is given concomitantly with MenACYW Conjugate vaccine and Tdap vaccine, compared to those when the first dose of HPV vaccine is given with Tdap vaccine only. Observational objective: * To describe the safety profile of MenACYW Conjugate vaccine, compared to that of the licensed vaccine MENVEO®, and when MenACYW Conjugate vaccine was given with Tdap and HPV vaccines.
Conditions
- Meningitis
- Meningococcal Meningitis
- Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate VaccineBiological
0.5 milliliter (mL), Intramuscular (IM)
Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate VaccineBiological
0.5 mL, IM
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine AdsorbedBiological
0.5 mL, IM
GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, RecombinantBiological
0.5 mL, IM
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate VaccineBiological
0.5 mL, Intramuscular (IM)
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine AdsorbedBiological
0.5 mL, IM
GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, RecombinantBiological
0.5 mL, IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® VaccineTime frame: Day 30 (post-vaccination)
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Downey, California
Site not named
San Diego, California
Site not named
Miami Beach, Florida
Site not named
Wichita, Kansas
Site not named
Bardstown, Kentucky
Site not named
Nicholasville, Kentucky
Site not named
Columbia, Maryland
Site not named
Lincoln, Nebraska
Site not named
Lincoln, Nebraska
Site not named
Lincoln, Nebraska
Site not named
Cleveland, Ohio
Site not named
Dayton, Ohio
Site not named
Norman, Oklahoma
Site not named
Erie, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Kingsport, Tennessee
Site not named
Tullahoma, Tennessee
Site not named
Layton, Utah
Site not named
Orem, Utah
Site not named
Payson, Utah
Site not named
Provo, Utah
Site not named
Roy, Utah
Site not named
Salt Lake City, Utah
Site not named
Salt Lake City, Utah
Site not named
South Jordan, Utah
Site not named
Spanish Fork, Utah
Site not named
Syracuse, Utah
Site not named
West Haven, Utah
Site not named
West Jordan, Utah
Site not named
Charlottesville, Virginia
Site not named
Midlothian, Virginia
Site not named
Spokane, Washington
Site not named
Spokane, Washington
Site not named
San Juan, PR, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.